Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Gag Peptide Sequence
HIV-1 GAG peptide A-I is a specific peptide sequence derived from the HIV-1 Gag protein, functioning as a CD8+ T cell epitope. This reagent is instrumental in the study of immune responses to HIV-1 infection and plays a critical role in HIV vaccine research. Its application is essential for the evaluation of T cell responses in vaccine candidates and the characterization of immune recognition patterns. -
HIV-1 Polypeptide
MPG is a 27-amino acid peptide derived from the nuclear localization sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. This peptide functions as an effective delivery agent for the transfection of nucleic acids and oligonucleotides into cultured cells. Its ability to facilitate cellular uptake of genetic material makes MPG a valuable tool for research applications in gene therapy and molecular biology. -
12-mer Peptide
Capsid assembly inhibitor is a 12-mer peptide that specifically targets the capsid (CA) domain of the Gag protein, effectively inhibiting the assembly of both immature and mature HIV-1 capsid particles in vitro. This compound serves as a valuable tool for studying HIV-1 replication mechanisms and evaluating potential antiviral strategies. Its ability to interfere with capsid formation makes it ideal for research in virology and the development of therapeutic agents against HIV-1. -
Antimicrobial Peptide
GLR-19 is an antimicrobial peptide with demonstrated anti-HIV properties. In addition to its efficacy against HIV, GLR-19 exhibits antiviral activity against herpes simplex virus type 2 (HSV-2). This compound is valuable for research applications focused on viral infections and the development of novel antiviral therapies. -
Epitope Peptide
HIV gag peptide (197-205) is an H-2Kd-restricted epitope derived from the p24 region of the HIV-1 gag protein, comprising the amino acid sequence AMQMLKETI. This peptide serves as a crucial tool for studying HIV-1 immune responses and T cell recognition. It is commonly utilized in vaccine development and immunological assays to analyze T cell activation and receptor specificity against HIV-1. -
Bioactive Peptide
Pol (476-484), HIV-1 RT Epitope is a bioactive peptide corresponding to residues 476-484 of the reverse transcriptase (RT) protein in HIV-1. This peptide acts as a dominant HLA A*0201-restricted epitope, playing a critical role in the immune response to HIV-1. It has been utilized in research to explore mechanisms underlying HIV-1 escape from cytotoxic T lymphocyte (CTL) recognition and is relevant for studying viral pathogenesis and developing vaccine strategies. -
Antimicrobial Peptide
Temporin C is an antimicrobial peptide that targets Legionella pneumophila. It exhibits significant antibacterial activity, making it a valuable tool for studying bacterial infections and developing new antimicrobial strategies. Its unique properties can aid in research focused on host-pathogen interactions and the development of novel therapeutic agents against bacterial pathogens. -
Antimicrobial Peptide
Temporin F is an antimicrobial peptide that exhibits activity against Legionella pneumophila, a pathogen responsible for severe pneumonia. This peptide targets bacterial membranes, disrupting their integrity and leading to cell death. Temporin F is valuable for research in antimicrobial resistance and the development of new therapeutic strategies against bacterial infections. -
Antimicrobial Peptide
Mastoparan B is an antimicrobial peptide derived from the venom of the hornet Vespa. This compound exhibits significant antimicrobial activity, disrupting cellular membranes and leading to cellular lysis. Mastoparan B's unique ability to alter the morphology of red blood cells from a standard disk shape to a serrated form makes it a valuable tool for studying membrane dynamics and cell morphology in various biological applications. It is particularly useful in research involving cell membrane interactions and antimicrobial efficacy. -
Antimicrobial Peptide
Peptide 5g is an antimicrobial peptide that exhibits potent activity against pathogenic microorganisms. It demonstrates inhibitory effects on Escherichia coli, Staphylococcus aureus, and Candida albicans, with minimal inhibitory concentration (MIC) values of 30, 10, and 12.5 μg/mL, respectively. This peptide can be utilized in research applications focused on the development of antimicrobial therapies and understanding the mechanisms of microbial resistance. -
HLA Class I-restricted CMV Peptide Epitope
VTEHDTLLY is an HLA class I-restricted peptide epitope derived from cytomegalovirus (CMV). It plays a crucial role in the activation and expansion of CMV-specific T cells, making it valuable for studying T cell responses in viral infections. This peptide can be utilized in both in vitro and in vivo research applications focused on immunology and vaccine development targeting CMV. -
CMV Peptide
CMV pp65 (415-429) is a synthetic peptide derived from the Cytomegalovirus (CMV) pp65 protein, serving as a control for cytomegalovirus-specific T cell responses. This peptide is utilized in various research applications including the assessment of cell-mediated immune responses and the study of CMV pathogenesis. Its specific features make it an essential tool for investigating CMV-related immune responses in both clinical and laboratory settings. -
CMV Epitope Peptides Fragment
CEF20 is a cytomegalovirus (CMV) pp65 epitope peptide fragment that is restricted by HLA-A*0201. This peptide, corresponding to amino acids 495-503, is useful for immunological studies focused on CMV-specific T cell responses. CEF20 can aid in the development of diagnostic assays and therapeutic strategies targeting CMV infections and is instrumental in research related to adaptive immunity. -
Antigen Peptide
IE1 peptide is an antigenic peptide derived from the immediate early (IE) gene of mouse cytomegalovirus (mCMV). It is critical for transcriptional activation during the mCMV replication cycle and serves as one of the earliest expressed viral genes. This peptide is a significant target for CD8+ T cell responses, making it valuable for research focused on host immune responses to mCMV infection. -
Anti-HIV Synthetic Peptides
T-22 is an anti-HIV synthetic peptide that specifically targets viral entry by disrupting the fusion process of the virus with host cells. Demonstrating potent antiviral activity with an EC50 of 0.008 μg/mL, T-22 exhibits a CC50 of 54 μg/mL, indicating its relative safety for cellular application. In addition to its antiviral properties, T-22 has been shown to enhance plant growth, photosynthesis, total chlorophyll content, and gas exchange in tomatoes, as well as provide resistance against Cucumber Mosaic Virus (CMV). This multifunctional peptide serves as a valuable tool in both virology and agricultural research. -
Antimicrobial Peptides
Hs-1 is an antimicrobial peptide that exhibits significant antiviral activity, offering approximately 80% protection against the dengue-2 virus. This peptide is valuable for research into therapeutic agents targeting viral infections. Its mechanism involves perturbation of viral membrane integrity, making it a useful tool for studies on peptide-based antiviral strategies. -
Polypeptide
2A/2B Dengue protease substrate (Ac-RTSKKR-pNA) is a polypeptide substrate designed for the Dengue NS2B-NS3 protease. This substrate facilitates the understanding of protease activity by serving as a valuable tool in the development of selective inhibitors targeting the Dengue NS2B-NS3 protease. Its efficacy in research applications enhances the study of dengue virus pathogenesis and potential therapeutic strategies. -
EBV Peptide
EBNA3 246-254 (RYSIFFDYM) is an Epstein-Barr Virus (EBV) peptide that targets HLA-A24. This peptide is instrumental in the amplification of EBV-specific cytotoxic T lymphocytes (CTLs) through in vitro techniques, followed by HLA multimer staining. EBNA3 246-254 serves as a valuable tool for researching EBV-related pathologies, including lung cancer. -
Peptide Antigen
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from the Epstein-Barr Virus (EBV) nuclear antigen 3B protein. This peptide is significant in studies related to EBV-associated malignancies and immune response. It is commonly utilized in research applications focusing on T-cell activation, antigen presentation, and vaccine development targeting EBV infections. -
Bioactive Peptide
BMLF1 (280–288) is a bioactive peptide derived from the Epstein-Barr Virus lytic protein, specifically targeting the HLA A2.1-restricted epitope. This peptide exhibits immunogenic properties and is utilized in research applications focused on antigen presentation and immune response studies. BMLF1 (280–288) serves as a valuable tool for investigating T cell activation and viral immunology. -
Immunogenic Peptide
IALYLQQNW is an immunogenic nonapeptide derived from the latent membrane protein 1 (LMP1) of the Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW effectively activates EBV-specific cytotoxic T lymphocytes (CTLs), facilitating the recognition and destruction of EBV-infected cells. This peptide is significant for investigating immune responses to EBV-associated malignancies, including Hodgkin's disease and nasopharyngeal carcinoma. It serves as a valuable tool for research into targeted immunotherapies and vaccine development against these cancers. -
Viral Antigen Peptide
EBNA-1 (386–405 aa) is a viral antigen peptide that exhibits cross-reactivity through its significant amino acid similarity to GlialCAM (370-389 aa). It induces the production of cross-reactive antibodies that target both Epstein-Barr virus (EBV) antigens and glial cells in the central nervous system, potentially initiating autoimmune responses. This peptide is valuable for research applications related to EBV infection and the pathophysiology of multiple sclerosis (MS). -
Single Peptide Epitope
CEF19 is a single peptide epitope derived from residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). This epitope plays a critical role in enhancing cytotoxic T-lymphocyte (CTL) recognition, making it a valuable tool for studying EBV-associated immune responses. CEF19 is applicable in research focused on viral pathogenesis, immune evasion, and vaccine development related to EBV infections. -
Bioactive Peptide
Epstein-Barr Virus BRLF1 (134-142) is a bioactive peptide that serves as a HLA-A11 restricted epitope derived from the BRLF1 protein of Epstein-Barr Virus. This peptide is valuable for research applications focusing on immune responses to viral infections, particularly in the context of Epstein-Barr Virus. It can aid in the development of vaccines and therapeutic strategies targeting EBV-related diseases. -
Antiviral Peptide
P9R is an antiviral peptide that exhibits broad-spectrum activity against multiple viruses, including coronaviruses (SARS-CoV-2, MERS-CoV, SARS-CoV), A(H1N1)pdm09, A(H7N9), and rhinovirus. Its primary mechanism involves direct binding to viral particles and inhibition of virus-host endosomal acidification, providing significant protection in murine models against A(H1N1)pdm09 infection without fostering drug resistance. P9R serves as a valuable research tool for studying pH-dependent respiratory viruses. -
Peptide
HBV Seq1 aa:141-151 is a peptide targeting the hepatitis B virus (HBV). This peptide is instrumental for research into the mechanisms of chronic HBV infection and immune response. It facilitates the study of viral epitope recognition and potential therapeutic interventions in HBV-related diseases. -
Cell-penetrating Peptide
Xentry is a cell-penetrating peptide (CPP) derived from the hepatitis B virus, featuring a sequence of seven amino acids (LCLRPVG). This peptide facilitates the efficient delivery of large biomolecules, such as antibodies, siRNAs, and enzymes, to various tissues in vivo, excluding circulating blood cells. Studies demonstrate that Xentry conjugated with anti-B-raf antibodies or siRNAs effectively induces cell death in B-raf-dependent melanoma cells, highlighting its potential in targeted cancer research and therapeutic applications. -
HBsAg Epitope Peptide
HBV Seq2 aa:208-216 is a HBsAg-derived CD8 epitope peptide targeting the immune response to Hepatitis B virus. This peptide plays a critical role in studying T cell recognition and can be utilized in vaccine development and immunological assays. Its application aids in understanding the host's immune response to HBV, contributing to research on therapeutic strategies against hepatitis B infection. -
PreS2 peptide
Hepatitis B Virus PreS Region (120-145) is a preS2 peptide that specifically inhibits the binding of single-chain variable fragment (scFv) or IgG to recombinant Hepatitis B surface antigen (r-HBsAg). This peptide serves as a valuable tool for studying Hepatitis B virus interactions and vaccine development, enabling researchers to explore therapeutic targets and improve diagnostic methods related to Hepatitis B infection. Its ability to disrupt binding makes it suitable for applications in immunology and virology research. -
HBsAg Peptide
HBV Seq2 aa:28-39 is a peptide derived from Hepatitis B Surface Antigen (HBsAg) that specifically interacts with major histocompatibility complex (MHC) class I molecules. This interaction is crucial for the activation of CD8+ T cells, making it an important tool for studying immune responses to HBV infection. It is widely used in vaccine research and T cell epitope mapping to enhance understanding of viral pathogenesis and immune evasion mechanisms. -
Depsipeptide
Destruxin B2 is a natural depsipeptide that primarily targets the secretion of hepatitis B surface antigen (HBsAg). It exhibits significant biological activity, with an IC50 value of 1.30 μM in inhibiting HBsAg secretion in Hep3B cells. This compound is valuable for research applications focusing on hepatitis B virus infection and potential therapeutic strategies. -
HCV Core Protein
HCV Peptide (35-44) is a peptide derived from the HCV core protein, specifically spanning positions 35 to 44, serving as an HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. This peptide is known to inhibit natural killer (NK) cell activity through two distinct mechanisms: direct interaction with KIR2DL2/3 and a synergistic effect via the CD94:NKG2A receptor. Its characterization is essential for research into HCV immunology and the development of therapeutic strategies targeting viral evasion of the immune response. -
Peptide
HCV Peptide (131-140) is a synthetic peptide derived from the hepatitis C virus (HCV) proteome. This peptide can be utilized in research focused on understanding HCV biology, immune response, and vaccine development. Its application extends to studies on viral protein interactions and the design of therapeutic strategies against hepatitis C infection. -
Tool Peptide
KK4A peptide is a tool peptide derived from the nonstructural protein 4A (NS4A) of the hepatitis C virus (HCV). It significantly enhances the catalytic efficiency of the NS3 protease, facilitating studies on HCV proteolytic mechanisms. This peptide serves as an invaluable resource for researchers investigating the function of NS3 protease and its role in HCV infection, contributing to the development of therapeutic strategies against hepatitis C. -
HCV NS4A Peptide
HCV NS4A Protein (18-40) (JT strain) is a peptide derived from the NS4A region of the hepatitis C virus, specifically comprising residues 18 to 40. This peptide enhances the catalytic efficiency of the NS3 protease, playing a crucial role in the viral lifecycle. It is valuable for research applications focused on understanding HCV replication mechanisms and developing antiviral therapies. -
Polypeptide
HCV-1 e2 Protein (484-499) is a polypeptide comprising 16 amino acids, derived from the envelope 2 (E2) protein of the hepatitis C virus. This peptide serves as a valuable tool for immunological studies, particularly in the analysis of antibody responses in individuals infected with HCV. Its applications extend to vaccine development and understanding virus-host interactions, facilitating advancements in hepatitis C research. -
Peptide
HCV Peptide (257-266) is a synthetic peptide derived from the hepatitis C virus (HCV) that targets immune responses associated with HCV infection. It is primarily utilized in research to study HCV-specific T-cell responses and to develop potential therapeutic strategies. This peptide is instrumental in understanding the pathogenesis of hepatitis C and may aid in vaccine development and immune modulation studies. -
HCV Peptide
HCV Core Protein (59-68) is a peptide derived from residues 59-68 of the Hepatitis C Virus (HCV) core protein. This peptide serves as an essential tool for studying HCV pathogenesis and immunological responses. It is commonly used in research applications such as vaccine development, peptide-based immunoassays, and understanding viral entry mechanisms. -
Synthetic Peptide
PQDVKFP is a synthetic peptide that targets antigenic domains of the hepatitis C virus (HCV) core protein. This peptide is valuable for the development of diagnostic assays and research focused on the immune response to HCV. Its specificity may facilitate studies into HCV pathogenesis and vaccine development. -
Antimicrobial Peptide
PP13 is an antimicrobial peptide that exhibits activity against both Gram-negative and Gram-positive bacteria, demonstrating minimum inhibitory concentrations (MIC) of 16.7 µM against E. coli, 13.3 µM against B. subtilis, 23.3 µM against S. aureus, 8.0 µM against S. lutea, and 9.0 µM against B. pumilus. This potent peptide is useful in research applications focused on microbial resistance and the development of novel antimicrobial agents. Its broad-spectrum efficacy makes it a valuable tool for studying bacterial infections and designing therapeutic strategies. -
Antibacterial Peptide
Latarcin 2a is a linear cationic antibacterial peptide derived from the venom of the spider Lachesana tarabaevi, exhibiting broad-spectrum antibacterial activity. It demonstrates a minimum inhibitory concentration (MIC) of 0.5 μM against both Bacillus subtilis and Escherichia coli. This peptide is primarily utilized in research related to infectious diseases and the development of novel antimicrobial agents. -
Peptide
Tetanus toxin (1301-1315) (C. tetani) is a C-terminal peptide fragment derived from the heavy chain of the tetanus toxin produced by Clostridium tetani. This peptide is instrumental in research related to pathogen-host interactions and immune responses. It serves as a valuable tool for studying tetanus infection mechanisms and potential therapeutic approaches in immunology. -
Antimicrobial Peptide
rCRAMP (rat) is a cathelin-related antimicrobial peptide that plays a crucial role in the innate immune response within the rat central nervous system. This peptide demonstrates significant antibacterial properties when extracted from rat brain tissues, highlighting its relevance in neuroimmunology research. Investigations into rCRAMP (rat) can provide insights into its potential therapeutic applications in combating infections and promoting brain health. -
Antimicrobial Peptide
Cyclopetide 2 is an antimicrobial peptide that exhibits moderate antibacterial activity against Bacillus subtilis, with a minimum inhibitory concentration (MIC) of 50 μg/mL. This compound is valuable for research applications focused on the development of antimicrobial agents and the study of peptide-based therapeutics. Its effectiveness in inhibiting bacterial growth makes it a relevant tool for exploring peptide interactions with microbial targets. -
Antimicrobial Peptide
Api137 is an antimicrobial peptide that targets bacterial ribosomes, inhibiting protein synthesis through the entrapment of release factors on the 70S ribosome after the hydrolysis of the nascent polypeptide chain. This mechanism effectively disrupts bacterial growth and viability. Api137 is utilized in research applications focused on understanding antibiotic resistance and exploring novel antimicrobial strategies. -
Antimicrobial Peptide
XT-2 peptide is an antimicrobial peptide derived from the skin secretions of Xenopus tropicalis. It exhibits significant antibacterial activity against Escherichia coli, with a minimum inhibitory concentration (MIC) of 8 μM. XT-2 peptide is useful in research applications focused on therapeutic interventions for bacterial infections and the study of host defense mechanisms. -
Antimicrobial Peptide
Apidaecin IA is an antimicrobial peptide that primarily targets bacterial membranes. This peptide exhibits significant antibacterial activity against a range of Gram-negative bacteria, making it a valuable candidate for research into novel antimicrobial therapies. Its unique mechanism of action and efficacy position it as a potential lead compound for the development of new antimicrobial agents in the fight against antibiotic-resistant infections. -
Antibacterial Peptide
CP7-FP13-2 is an antibacterial peptide that targets virulence factors in bacteria. It effectively inhibits the formation of biofilms in Staphylococcus aureus, demonstrating potent antibacterial activity in in vivo mouse models. This compound is valuable for research applications focusing on microbial resistance and the development of alternative therapeutic strategies against bacterial infections. -
Cyclic Dipeptide
Cyclo(Gly-His) is a cyclic dipeptide that exhibits antimicrobial and anticancer properties. It demonstrates significant cytotoxicity against HeLa and MCF-7 cells, with IC50 values of 1.699 mM and 0.358 mM, respectively. This compound is valuable for research in drug delivery systems and exploring its potential as a therapeutic agent. -
Antimicrobial Peptide
Maximin 4 is an antimicrobial peptide derived from the skin secretions of Bombina maxima. This peptide exhibits significant cytotoxic effects on tumor cells and demonstrates spermicidal activity. Its unique properties make it a valuable tool for research applications in cancer biology and reproductive health studies.
